Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Lundgren, Julie R.; Janus, Charlotte; Jensen, Simon B. K.; Juhl, Christian R.; Olsen, Lisa M.; Christensen, Rasmus M.; Svane, Maria S.; Bandholm, Thomas; Bojsen-Møller, Kirstine N.; Blond, Martin B.; Jensen, Jens-Erik B.; Stallknecht, Bente M.; Holst, Jens J.; Madsbad, Sten; Torekov, Signe S.

Published in:
New England Journal of Medicine

DOI:
10.1056/NEJMo2028198

Publication date:
2021

Document version
Publisher's PDF, also known as Version of record

Document license:
Other

Citation for published version (APA):
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined


BACKGROUND
Weight regain after weight loss is a major problem in the treatment of persons with obesity.

METHODS
In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed.

RESULTS
After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, −4.1 kg (95% confidence interval [CI], −7.8 to −0.4; P = 0.03); in the liraglutide group, −6.8 kg (95% CI, −10.4 to −3.1; P<0.001); and in the combination group, −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, −5.4 kg; 95% CI, −9.0 to −1.7; P=0.004) but not liraglutide (−2.7 kg; 95% CI, −6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (−1.7 percentage points; 95% CI, −3.2 to −0.2; P=0.02) and the liraglutide group (−1.9 percentage points; 95% CI, −3.3 to −0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group.

CONCLUSIONS
A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.)
The prevalence of obesity is increasing,\(^1\) with detrimental effects on health.\(^2\)

Obesity is characterized by excess body fat and is associated with physical inactivity,\(^3\) which also impairs health and increases the risk of death.\(^4\) A decrease in body weight of 3 to 5% has been associated with reduced obesity-related risk factors, although a larger weight loss of more than 5 to 15% of the initial body weight is recommended for patients with coexisting conditions, morbid obesity, or both.\(^5,6\) Many patients have an initial large weight loss, but weight regain often occurs\(^6,7\) unless a structured weight-maintenance program is followed. Rapid weight regain may be due to a reduction in total energy expenditure, beyond that predicted from the loss of lean and fat mass,\(^8\) and to increased appetite.\(^9,10\)

Structured aerobic exercise programs increase energy expenditure and cardiorespiratory fitness while reducing fat mass and preserving or increasing lean mass.\(^11,12\) Diet management programs, including the use of low-calorie meal-replacement products, can sustain low-calorie diet–induced weight loss with a small weight regain.\(^11,15,16\) Furthermore, lifestyle interventions that encourage increased physical activity concurrent with calorie restriction have been shown to sustain moderate weight loss.\(^10,15\) However, the isolated benefits of exercise to prevent weight regain after weight loss is understudied.\(^20\)

Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is used in the treatment of obesity because it induces weight loss\(^21-23\) and maintains low-calorie diet–induced weight loss for at least 1 year,\(^11,24\) primarily by means of appetite inhibition.\(^25\) Whether exercise, medication, or a combination strategy constitutes the more effective approach for maintaining healthy weight loss remains an open question. We investigated the efficacy of 1-year treatment with a moderate-to-vigorous–intensity exercise program, liraglutide at a dose of 3.0 mg per day, or the combination of exercise plus liraglutide, as compared with placebo, for healthy weight loss maintenance after weight loss induced by a low-calorie diet.

**METHODS**

**TRIAL DESIGN AND OVERSIGHT**

We conducted this investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen, Denmark. Participants followed a low-calorie diet of 800 kcal per day (Cambridge Weight Plan) for 8 weeks. All the participants who had a weight loss of at least 5% of their baseline body weight were randomly assigned, in a 1:1:1:1 ratio, to one of the following treatment strategies for 1 year: exercise plus placebo (exercise group), liraglutide plus usual activity (liraglutide group), exercise plus liraglutide (combination group), or placebo plus usual activity (placebo group). Randomization was stratified according to sex and age (<40 years vs. ≥40 years of age) (see Methods Section A in the Supplementary Appendix, available with the full text of this article at NEJM.org).

Participants, assessors, and investigators were unaware of the trial-group assignments with regard to liraglutide or placebo. To support the maintenance of weight loss after randomization, all the participants were to attend 12 individual consultations that included measurement of body weight and dietetic support complying with the dietetic recommendations for sustained weight loss from the Danish authorities (see Methods Section B in the Supplementary Appendix). The trial was approved by the local ethics committee and the Danish Medicines Agency and was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All the participants provided written informed consent before the first trial visit.

Our primary trial report adheres to the CONSORT (Consolidated Standards of Reporting Trials) guidelines. The trial design has been published previously,\(^26\) and the protocol, with the statistical analysis plan, is available at NEJM.org.

Eight of the authors designed the trial, and nine authors gathered data. Statistical analyses of hypothesis-based end points (change in body weight [primary] and body-fat percentage [secondary]) were performed in a blinded manner with regard to group assignment by a statistical assessor who is an author but who was not involved in the trial design and execution. Four of the authors analyzed other end points. All the authors had full access to all the data and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. The first four authors and the last author wrote the first draft of the manuscript, which all the authors edited and approved. All the authors agreed to submit the manuscript for publication.

Novo Nordisk supplied liraglutide and placebo injector pens, and Cambridge Weight Plan suppl-
plied diet-replacement products for the low-calorie-diet phase. The funding partners did not influence or take part in the execution of the trial; in the collection, analysis, ownership, or interpretation of the data; or in the communication of the trial results.

PARTICIPANTS

Eligible participants were adults (18 to 65 years of age) with obesity, which was defined as a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 32 to 43. Diabetes (type 1 or 2) was a major exclusion criterion. Full lists of the inclusion and exclusion criteria are provided in Table S1 of the Supplementary Appendix.

INTERVENTIONS

The exercise program was designed to meet the World Health Organization (WHO) recommendations on physical activity for health of a minimum of 150 minutes per week of moderate-intensity aerobic physical activity, or 75 minutes per week of vigorous-intensity aerobic physical activity, or an equivalent combination of both. Each participant was assigned to an instructor (who had a bachelor’s or master’s degree in exercise physiology) who planned and monitored the individualized programs. After an initial 6-week ramp-up phase, participants were encouraged to attend supervised group exercise sessions (which involved 30 minutes of vigorous-intensity, interval-based indoor cycling and 15 minutes of circuit training) two times per week and to perform moderate-to-vigorous-intensity exercise individually (which mostly involved outdoor or indoor cycling, running, or brisk walking) two times per week. Heart-rate monitors were worn at all exercise sessions to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity was met.

The exercise program was structured but flexible, which meant that participants could substitute group exercise with individual exercise or vice versa; participants could also reduce exercise frequency if the duration was prolonged or the intensity was increased. Modifications were made in agreement between the participant and instructor if deemed necessary in order to reach the sufficient exercise volume (duration × intensity). Adherence was based on the weekly exercise volume. A detailed program description is provided in Methods Section D in the Supplementary Appendix. Participants who were not randomly assigned to trial exercise (i.e., those in the placebo group or liraglutide group) were instructed to maintain usual physical activity.

Liraglutide (at a concentration of 6 mg per milliliter) or volume-matched placebo was injected subcutaneously, starting at a dose of 0.6 mg per day, with supervised weekly increments of 0.6 mg per day; the dose was intended to eventually reach 3.0 mg per day. Participants who had unacceptable adverse effects at a given dose received the maximum dose at which they did not have such effects. Participants remained enrolled in the trial if the use of liraglutide or placebo was discontinued (see Methods Section C in the Supplementary Appendix).

END POINTS

The primary end point was the change in body weight (in kilograms) from randomization to week 52. The secondary end point was the change in the percentage of body fat (calculated as the fat mass [in kilograms] divided by the body weight [in kilograms], times 100) from randomization to week 52. Body weight was measured before the prerandomization low-calorie diet was started, at randomization, and at weeks 1, 2, 4, 9, 13, 17, 22, 26, 32, 39, 46, and 52. The percentage of body fat was measured by means of dual-energy x-ray absorptiometry (Hologic Discovery) before the low-calorie diet was started, at randomization, and at week 52.

Prespecified metabolic health-related end points included changes from randomization to week 52 in fat mass, lean mass, cardiorespiratory fitness, glycated hemoglobin level, indexes of insulin resistance during fasting (liver insulin resistance, as assessed by the homeostatic model assessment of insulin resistance [HOMA-IR]) and during meal intake (whole-body insulin resistance, as assessed by the Matsuda index), lipid levels, quality of life, waist and hip circumferences, waist-to-hip ratio, blood pressure, and resting heart rate (see Methods Section G in the Supplementary Appendix). Adverse events and the dose of liraglutide or placebo were reported and registered at all visits.

STATISTICAL ANALYSIS

We estimated that a sample of 30 participants in each group would provide the trial with 80% power to detect a minimal clinically important difference in the primary end point, the change
A Change in Body Weight

-4.1 (95% CI, −7.8 to −0.4) 7
−6.8 (95% CI, −10.4 to −3.1) 4
−9.5 (95% CI, −13.1 to −5.9) 3
−5.4 (95% CI, −9.0 to −1.7) 4
−2.7 (95% CI, −3.8 to −0.7) 8

B Change in Body-Fat Percentage

−2.2 (95% CI, −3.8 to −0.7) 7
−1.9 (95% CI, −3.3 to −0.5) 4
−1.7 (95% CI, −3.2 to −0.2) 3

C Change in Body Weight from Wk −8 to Wk 52

-6.7 4
−10.9 3
−13.4 2
−15.7 1
in body weight, of 4.0 kg at an alpha level of 0.05. For the secondary end point, the change in body-fat percentage, we estimated that a sample of 32 participants in each group would provide the trial with 80% power to detect a minimal clinically important difference of 1.5 percentage points at an alpha level of 0.05. We anticipated that 68% of the participants would complete the trial (see item 11 in the statistical analysis plan, which is available with the protocol).

In accordance with the prespecified statistical analysis plan, eight hypotheses for the primary and secondary end points were tested hierarchically (see the Hypotheses: Analysis Results and Claims section in the Supplementary Appendix). The analyses were performed in the intention-to-treat population.

End points were analyzed with the use of a repeated-measures linear regression model, which included time (factorial), trial group, sex, age group (<40 years vs. ≥40 years), and a time–group interaction as explanatory variables and a repeated effect for visit. A multivariate normal error structure was assumed in the model. All missing data were assumed to be missing at random. Three prespecified supplementary analyses were performed regarding body weight and body-fat percentage — a per-protocol analysis (which excluded participants who had deviations from the protocol), an analysis with adjustment for initial weight loss during the low-calorie diet (to assess the effect of missing data by incorporating further information), and an analysis that used multiple imputations (under the assumption that participants who were lost to follow-up would have a response as if they received placebo, in order to challenge the assumption that data were missing at random) (see items 27 and 28 in the statistical analysis plan). Prespecified end points without hypotheses are reported as point estimates with 95% confidence intervals that were unadjusted for multiple testing, so definite inferences cannot be made regarding those end points.

**RESULTS**

**TRIAL POPULATION**

The trial was conducted from August 2016 through November 2019. A total of 215 participants initiated the low-calorie diet, of whom 195 had a weight loss of at least 5% of their baseline body weight; these 195 participants underwent randomization. A total of 166 participants (85%), including 40 of 48 (83%) in the exercise group, 41 of 49 (84%) in the liraglutide group, 45 of 49 (92%) in the combination group, and 40 of 49 (82%) in the placebo group, attended the visit for the assessment of the primary end point at week 52 (Fig. 1A and Table S13). The reasons that participants missed the assessment visit are shown in Figure S1. The demographic characteristics of the participants at randomization were similar across the trial groups (Table S3).

**LOW-CALORIE DIET**

The characteristics of the participants before and after the low-calorie diet are shown in Table 1. During the 8-week low-calorie diet, the participants’ body weight decreased by a mean of 13.1 kg (95% confidence interval [CI], 12.4 to 13.7), which was equivalent to a mean reduction in body weight of 12%. This decrease was accompanied by decreases in the body-fat percentage, waist circumference, waist-to-hip ratio, glycated
Table 1. Characteristics of the Participants before and after 8 Weeks of a Low-Calorie Diet.*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Before Low-Calorie Diet (N = 215)</th>
<th>After Low-Calorie Diet, at Randomization (N = 195)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex — no. (%)</td>
<td>Male 80 (37)</td>
<td>71 (36)</td>
</tr>
<tr>
<td></td>
<td>Female 135 (63)</td>
<td>124 (64)</td>
</tr>
<tr>
<td>Age — yr</td>
<td>42±12</td>
<td>43±12</td>
</tr>
<tr>
<td>Body weight — kg</td>
<td>109.7±14.9</td>
<td>96.7±12.5</td>
</tr>
<tr>
<td>Body-mass index</td>
<td>37.0±2.9</td>
<td>32.6±2.9</td>
</tr>
<tr>
<td>Body-fat percentage — %</td>
<td>41.1±6.1</td>
<td>38.6±6.9</td>
</tr>
<tr>
<td>Fat mass — kg</td>
<td>44.9±7.2</td>
<td>37.7±7.2</td>
</tr>
<tr>
<td>Lean mass — kg</td>
<td>65.3±12.9</td>
<td>60.4±11.6</td>
</tr>
<tr>
<td>Waist circumference — cm</td>
<td>110.6±11.3</td>
<td>100.3±10.0</td>
</tr>
<tr>
<td>Hip circumference — cm</td>
<td>121.4±7.5</td>
<td>113.9±7.3</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.91±0.10</td>
<td>0.88±0.10</td>
</tr>
<tr>
<td>Cardiorespiratory fitness — ml/min/kg†</td>
<td>22.9±4.2</td>
<td>24.9±5.4</td>
</tr>
<tr>
<td>Glycated hemoglobin — mmol/mol</td>
<td>36±4</td>
<td>34±3</td>
</tr>
<tr>
<td>Blood pressure — mm Hg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>132±16</td>
<td>122±13</td>
</tr>
<tr>
<td>Diastolic</td>
<td>86±10</td>
<td>79±8</td>
</tr>
<tr>
<td>Resting heart rate — beats/min</td>
<td>73±10</td>
<td>69±12</td>
</tr>
<tr>
<td>HOMA-IR‡</td>
<td>3.9±2.4</td>
<td>1.7±1.0</td>
</tr>
<tr>
<td>Matsuda index§</td>
<td>2.7±1.8</td>
<td>4.9±2.7</td>
</tr>
<tr>
<td>Cholesterol — mmol/liter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>5.0±1.0</td>
<td>4.1±0.8</td>
</tr>
<tr>
<td>Low-density lipoprotein</td>
<td>3.1±0.8</td>
<td>2.5±0.8</td>
</tr>
<tr>
<td>High-density lipoprotein</td>
<td>1.3±0.3</td>
<td>1.1±0.3</td>
</tr>
<tr>
<td>Triglycerides — mmol/liter</td>
<td>1.5±0.9</td>
<td>1.1±0.4</td>
</tr>
<tr>
<td>RAND-36 score¶</td>
<td></td>
<td></td>
</tr>
<tr>
<td>General health perception</td>
<td>71±16</td>
<td>79±15</td>
</tr>
<tr>
<td>Physical functioning</td>
<td>86±13</td>
<td>91±11</td>
</tr>
<tr>
<td>Emotional well-being</td>
<td>81±12</td>
<td>84±11</td>
</tr>
</tbody>
</table>

* Plus–minus values are observed means ±SD. Among the 215 enrolled participants who began the low-calorie diet, those who had a weight loss at 8 weeks of at least 5% of their baseline body weight (195 participants) underwent randomization. The estimated mean changes (with 95% confidence intervals) during the low-calorie diet are shown in Table S2.

† Cardiorespiratory fitness was assessed as the peak oxygen consumption (in milliliters of oxygen per minute per kilogram of body weight).

‡ The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as the fasting insulin level (in milliunits per milliliter) times the fasting glucose level (in millimoles per liter), divided by 22.5. The conversion factor that was used for insulin was that 1 μU per milliliter was equal to 6.00 pmol per liter. The conversion factor that was used for glucose was that 1 mg per deciliter was equal to 0.05551 mmol per liter.

§ The Matsuda index was calculated as 10,000 divided by the square root of the following value: the fasting glucose level times the fasting insulin level times the mean glucose level times the mean insulin level.

¶ Scores on each domain of the RAND 36-Item Health Survey (RAND-36) range from 0 to 100, with higher scores indicating better health.
hemoglobin level, blood pressure, lipid levels, resting heart rate, and HOMA-IR. The Matsuda index, cardiorespiratory fitness, general health perception, physical functioning, and emotional well-being increased (Table S2).

### Weight Loss Maintenance at 1 Year

#### Adherence to Interventions

The mean (±SD) weekly duration of exercise was 118±74 minutes at an intensity of 78±4% of the maximum heart rate in the exercise group and 111±73 minutes at an intensity of 79±5% of the maximum heart rate in the combination group, which corresponded to adherence of 119±70% and 113±71%, respectively, of the WHO recommended exercise volume. Participants performed individually, with a similar mean intensity in the group and individual exercise sessions (Table S7).

The mean dose of liraglutide was 2.8±0.4 mg per day in the liraglutide group and 2.8±0.7 mg per day in the combination group; the mean dose of volume-matched placebo was 2.6±0.9 mg per day in the exercise group and 2.9±0.4 mg per day in the placebo group. Details are provided in Table S8.

### Body Weight and Body-Fat Percentage

After the low-calorie diet, the participants’ body weight decreased further by a mean of −3.4 kg in the combination group but increased by a mean of 6.1 kg in the placebo group, resulting in a treatment difference of −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The initial weight loss was maintained in the exercise group, with a treatment effect as compared with placebo of −4.1 kg (95% CI, −7.8 to −0.4; P=0.03). Liraglutide treatment also resulted in maintenance of the initial weight loss, with a treatment effect as compared with placebo of −6.8 kg (95% CI, −10.4 to −3.1; P<0.001). In the combination group, the treatment effect as compared with exercise was −5.4 kg (95% CI, −9.0 to −1.7; P=0.004) and the treatment effect as compared with liraglutide was −2.7 kg (95% CI, −6.3 to 0.8; P=0.13) (Fig. 1A and Table S4).

The percentages of participants in each group who had a total weight loss of at least 5%, at least 10%, at least 15%, and at least 20% of the baseline body weight are shown in Figure 1C. The mean total weight loss from before the low-calorie diet to the end of the trial was 15.7% of the baseline body weight in the combination group, 10.9% of the baseline weight in the exercise group, 13.4% of the baseline weight in the liraglutide group, and 6.7% of the baseline weight in the placebo group.

At 52 weeks, the reduction in the body-fat percentage was greater in the exercise group than in the placebo group, with a treatment effect of −2.2 percentage points (95% CI, −3.8 to −0.7; P=0.004); was greater in the liraglutide group than in the placebo group, with a treatment effect of −2.0 percentage points (95% CI, −3.5 to −0.6); and was greater in the combination group than in the placebo group, with a treatment effect of −3.9 percentage points (95% CI, −5.4 to −2.5). Thus, the body-fat percentage was further reduced in the combination group by −1.7 percentage points (95% CI, −3.2 to −0.2) as compared with the exercise group (P=0.02) and by −1.9 percentage points (95% CI, −3.3 to −0.5) as compared with the liraglutide group (P=0.009) (Fig. 1B and Table S4). The three supplementary analyses of the primary and secondary end points supported the results of the primary analysis (Tables S9 and S10).
physical functioning, as compared with placebo (Fig. 2D). All active treatments were associated with maintained reductions in the systolic and diastolic blood pressures, which were not observed with placebo (Tables S5 and S6). Exercise and the combination strategy were associated with maintenance of the initial improvements in general health perception and emotional well-being, which were not observed with placebo or liraglutide (Fig. 2E).
Safety

Adverse events that occurred in at least 10% of all participants, urinary tract infections, palpitations, and all serious adverse events are reported in Table 2; full lists of adverse events and serious adverse events are provided in Tables S11 and S12, respectively. Five participants (two receiving liraglutide and three receiving placebo) discontinued taking liraglutide or placebo because of adverse events. Gastrointestinal adverse events, decreased appetite, and dizziness were more frequently reported in the groups that received liraglutide (i.e., in the liraglutide group and combination group) than in the other two groups. Cholelithiasis as a serious adverse event and palpitations were reported more frequently in the liraglutide group than in the combination group. After 1 year, liraglutide treatment alone was associated with an increased resting heart rate; this finding was not observed with the combination strategy (Figs. 2F and S3). The incidence of other adverse events was similar among the trial groups.

Discussion

In this randomized, head-to-head, placebo-controlled trial, we investigated exercise, liraglutide, and both treatments combined for healthy weight loss maintenance. All active-treatment groups decreased body weight and body-fat percentage after 1 year, as compared with the increases observed in the placebo group. The combined strategy reduced the body weight and body-fat percentage approximately twice as much as the single-treatment strategies did and was associated with additional health benefits, such as improvements in the glycated hemoglobin level, insulin sensitivity, cardiorespiratory fitness, physical functioning, and emotional well-being.

The initial low-calorie diet resulted in a mean body-weight reduction of 12% of the baseline body weight among the participants who underwent randomization. After 1 year, the combination of exercise and liraglutide therapy induced an additional reduction in body weight, resulting in a total weight loss of 16%. This is more than the total weight losses of approximately 10% that were obtained with 1-year diet-management programs after an initial low-calorie diet.31,32,36,39

It is also more than the 1-year weight loss of 7 to 9% of the initial body weight that has been observed with concurrent intensive diet and physical activity programs.18,19 The total weight reduction was approximately similar to the 15% weight loss that was observed after 68 weeks of treatment with the GLP-1 receptor agonist semaglutide, administered subcutaneously at a dose of 2.4 mg once weekly as an adjunct to lifestyle change (currently not approved by any governmental medical agencies at this dose and for this indication).30 In our trial, participants in the placebo group regained, on average, 6.1 kg, which was equivalent to 45% of the weight that they had initially lost; this weight regain was accompanied by deterioration in all associated metabolic health-related improvements. This result shows the critical importance of implementing structured treatment after weight loss, as compared with a strategy of just 12 individualized consultations regarding weight and diet, as provided in the current trial according to the recommendations of the Danish authorities for sustained weight loss.

Exercise alone led to maintenance of the ini-
tial weight loss and further reduced body-fat percentage. Exercise (walking or resistance training) as a weight-loss maintenance strategy after diet-induced weight loss was previously reported as having a minor effect (<3 kg)\(^{31}\) or no effect.\(^{32}\) In contrast, the exercise program in this trial was predominantly of vigorous intensity, both at group sessions and individual sessions (mostly cycling and running) and with high adherence to WHO recommendations regarding physical activity volume. This strategy was associated with improved cardiorespiratory fitness, increased lean mass, and prevention of a 4-kg regain of body fat.

### Table 2. Adverse Events and Serious Adverse Events after Randomization.\(^*\)

<table>
<thead>
<tr>
<th>Event</th>
<th>All Participants (N = 195)</th>
<th>Placebo Group (N = 49)</th>
<th>Exercise Group (N = 48)</th>
<th>Liraglutide Group (N = 49)</th>
<th>Combination Group (N = 49)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adverse event</td>
<td>175 (90)</td>
<td>42 (86)</td>
<td>39 (81)</td>
<td>49 (100)</td>
<td>45 (92)</td>
</tr>
<tr>
<td>Gastrointestinal adverse event</td>
<td>130 (67)</td>
<td>22 (45)</td>
<td>31 (65)</td>
<td>42 (86)</td>
<td>35 (71)</td>
</tr>
<tr>
<td>Serious adverse event†</td>
<td>16 (8)</td>
<td>2 (4)</td>
<td>4 (8)</td>
<td>6 (12)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>Adverse event that led to the discontinuation of liraglutide or placebo</td>
<td>5 (3)</td>
<td>0</td>
<td>3 (6)</td>
<td>1 (2)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Adverse event that led to withdrawal from the trial</td>
<td>2 (1)</td>
<td>0</td>
<td>0</td>
<td>1 (2)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Adverse events that occurred in ≥10% of all participants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>81 (42)</td>
<td>8 (16)</td>
<td>15 (31)</td>
<td>32 (65)</td>
<td>26 (53)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>55 (28)</td>
<td>13 (27)</td>
<td>17 (35)</td>
<td>12 (24)</td>
<td>13 (27)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>46 (24)</td>
<td>3 (6)</td>
<td>13 (27)</td>
<td>18 (37)</td>
<td>12 (24)</td>
</tr>
<tr>
<td>Influenza or influenza-like symptoms</td>
<td>40 (21)</td>
<td>8 (16)</td>
<td>8 (17)</td>
<td>11 (22)</td>
<td>13 (27)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>40 (21)</td>
<td>2 (4)</td>
<td>4 (8)</td>
<td>18 (37)</td>
<td>16 (33)</td>
</tr>
<tr>
<td>Headache</td>
<td>40 (21)</td>
<td>9 (18)</td>
<td>10 (21)</td>
<td>10 (20)</td>
<td>11 (22)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>38 (19)</td>
<td>4 (8)</td>
<td>7 (15)</td>
<td>13 (27)</td>
<td>14 (29)</td>
</tr>
<tr>
<td>Constipation</td>
<td>34 (17)</td>
<td>6 (12)</td>
<td>7 (15)</td>
<td>9 (18)</td>
<td>12 (24)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>34 (17)</td>
<td>2 (4)</td>
<td>6 (12)</td>
<td>11 (22)</td>
<td>15 (31)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>34 (17)</td>
<td>4 (8)</td>
<td>9 (19)</td>
<td>7 (14)</td>
<td>14 (29)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>33 (17)</td>
<td>3 (6)</td>
<td>4 (8)</td>
<td>15 (31)</td>
<td>11 (22)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>33 (17)</td>
<td>4 (8)</td>
<td>6 (12)</td>
<td>15 (31)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>Flatulence or abdominal distention</td>
<td>22 (11)</td>
<td>5 (10)</td>
<td>4 (8)</td>
<td>5 (10)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>19 (10)</td>
<td>0</td>
<td>1 (2)</td>
<td>9 (18)</td>
<td>9 (18)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>17 (9)</td>
<td>3 (6)</td>
<td>5 (10)</td>
<td>6 (12)</td>
<td>3 (6)</td>
</tr>
<tr>
<td>Palpitations</td>
<td>9 (5)</td>
<td>1 (2)</td>
<td>0</td>
<td>6 (12)</td>
<td>2 (4)</td>
</tr>
</tbody>
</table>

* Adverse events and serious adverse events from randomization through week 52 among all participants are included in the table and are presented with the preferred terms in the Medical Dictionary for Regulatory Activities, version 23.1. Specific adverse events reported here are those that occurred in at least 10% of all participants; in addition, given their importance, urinary tract infections and palpitations are reported. All the adverse events and serious adverse events are listed in Tables S11 and S12, respectively.

† The following serious adverse events were reported: in the placebo group, abdominal pain without verified reason (in one participant) and urosepsis (in one); in the exercise group, abdominal pain without verified reason (in two), ileus (in one), and autoimmune hepatitis (in one); in the liraglutide group, abdominal pain without verified reason (in one), acute cholelithiasis (in two), acute pancreatitis due to cholelithiasis (in one), appendicitis (in one), and gastroenteritis (in one); and in the combination group, abdominal pain without verified reason (in two), acute cholelithiasis (in one), and broken shoulder due to a road traffic accident (in one).
Treatment with liraglutide alone resulted in maintenance of the initial weight loss, with a treatment effect as compared with placebo of −6.8 kg, which is similar to the results of previous studies, and was also associated with loss of fat mass. The combination of exercise and liraglutide treatment was associated with loss of fat mass and reduction in waist circumference that were approximately twice those observed with the single treatments, and it preserved lean mass.

Both the liraglutide group and the combination group had further reductions in the glycated hemoglobin level, which is generally considered to reduce the risk of new-onset diabetes. By contrast, the exercise group and the combination group were observed to have increased the participants' cardiorespiratory fitness at a magnitude that has been associated with a decreased risk of cardiovascular disease and decreased all-cause mortality, and these strategies also maintained improvements in general and emotional health.

In accordance with previous studies, we observed an increased heart rate with liraglutide alone. Increased heart rate is generally considered an adverse effect, associated with lower survival. We did not observe an increased resting heart rate when exercise was combined with liraglutide, a finding that supports the health-promoting potential of this combination.

The percentage of participants who completed the trial was high in all the groups (82 to 92%) and was highest in the combination group, which shows that a combination of moderate-to-vigorous-intensity exercise and liraglutide treatment is feasible. Only the combined treatment was associated with improvements in insulin sensitivity and physical functioning as compared with placebo.

A major strength of this trial was the structured but flexible exercise program with rigorous monitoring of exercise adherence. Our trial showed that 1 year of mostly vigorous-intensity exercise, performed approximately 2.4 times per week, as a weight-loss maintenance strategy was feasible in persons with obesity with a very low initial level of fitness. The finding that the 1-year trajectories with regard to body weight, waist-to-hip ratio, and adherence were stable in the exercising groups — in which participants had a loss of fat mass and increase in lean mass, along with improved emotional well-being — also support feasibility. Other strengths of our trial included the direct comparison of separate and combined effects of exercise and liraglutide and high-quality assessments of exercise adherence and cardiorespiratory fitness in addition to body weight.

Limitations of the trial include the fact that our results may not be generalizable to older persons (>65 years of age), persons with greater obesity (BMI of >43), patients with coexisting conditions (e.g., type 2 diabetes), and persons who have low adherence to participation in a moderate-to-vigorous-intensity exercise program or who are limited in their ability to perform moderate-to-vigorous-intensity exercise.

In this trial involving persons with obesity, the combination of a moderate-to-vigorous-intensity exercise program and liraglutide treatment after diet-induced weight loss was more effective in improving healthy weight loss than either treatment alone.

Presented in part at the 80th Annual Meeting of the American Diabetes Association (June 12–16, 2020) and the 56th Annual Meeting of the European Association for the Study of Diabetes (Sept. 21–25, 2020). Supported by an Excellence grant (NNF16OC0019968, to Dr. Torekov) from the Novo Nordisk Foundation, by a grant (to Dr. Torekov) from the Novo Nordisk Foundation for Basic Metabolic Research, by a grant (NNF15CC0018486, to Dr. Torekov) from the Novo Nordisk Foundation Tripartite Immunometabolism Consortium, by Helsefonden, by a Ph.D. grant (to Dr. Lundgren) from the Faculty of Health and Medical Sciences, University of Copenhagen, and by a Ph.D. grant (to Dr. Janus) from the Danish Diabetes Academy and Department of Biomedical Sciences, University of Copenhagen.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

REFERENCES
5. Logue J, Thompson L, Romanes F, Wilson DC, Thompson J, Sattar N. Man...
12. Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA 2007;297:2081-91.

Copyright © 2021 Massachusetts Medical Society.

The New England Journal of Medicine
Downloaded from nejm.org at Det Kongelige Bibliotek: Nationalbibliotek og Københavns Uni on November 1, 2021. For personal use only. No other uses without permission. Copyright © 2021 Massachusetts Medical Society. All rights reserved.